Secretomes in support of immune health

Immunis has developed a novel method to grow human cells for clinical use and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; our technology allows replacement of those factors. Our product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations.


Pre-Clinical Safety & Efficacy Studies

Third-party preclinical safety studies confirmed the product to be safe and well tolerated.

The product has been shown to benefit muscular atrophy, metabolic and vascular function, tissue inflammation, immune cell function and exosome/extracellular vesicle composition in several age and immune-associated disease indications.

Pre-clinical studies of our investigational secretome product show a decrease in arterial stiffness with age.


Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells

Dennis K Fix, Ziad S Mahmassani, Jonathan J Petrocelli, Naomi M M P de Hart, Patrick J Ferrara, Jessie S Painter, Gabriel Nistor, Thomas E Lane, Hans S Keirstead, Micah J Drummond

Read now
Clinical pipeline

Target: Muscle Atrophy

Immunis is currently conducting a Phase 1/2a clinical trial for muscle atrophy.


Phase 1/2a Clinical Trial for Muscle Atrophy

Immunis' Phase 1/2a clinical trial includes elderly individuals with muscle atrophy associated with knee osteoarthritis. These individuals are prone to sarcopenia or age-related muscle atophy, which can contribute to immobilization and exacerbate the negative effects of knee osteoarthritis.

Clinical trial listing: